Results 251 to 260 of about 1,543,966 (410)

Efficacy and Safety of ABBV‐154 for the Treatment of Active Rheumatoid Arthritis: A Phase 2b, Randomized, Placebo‐Controlled Trial

open access: yesArthritis &Rheumatology, EarlyView.
Objective Despite the availability of biologic and targeted synthetic disease‐modifying antirheumatic drugs (b/tsDMARDs) to treat rheumatoid arthritis (RA), many patients do not experience optimized disease control. Glucocorticoids are effective but have safety risks.
Frank Buttgereit   +13 more
wiley   +1 more source

Efficacy and safety of probiotic supplements on cognitive function: a systematic review and meta-analysis of randomized clinical trials. [PDF]

open access: yesBMC Complement Med Ther
Calzada-Gonzales N   +8 more
europepmc   +1 more source

Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis

open access: yesNew England Journal of Medicine, 2017
P. Mease   +11 more
semanticscholar   +1 more source

Pharmacodynamic Effects of Litifilimab in Lupus in a Randomized, Placebo‐Controlled Phase 2 Study: Rapid and Sustained Reductions in Type I Interferon‐Associated Gene Expression and Cytokines

open access: yesArthritis &Rheumatology, EarlyView.
Objective The pharmacodynamic effects of litifilimab on type I interferon (IFN) response and correlations with clinical outcomes were investigated in systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE). Methods Participants from part A (SLE) or part B (CLE with or without SLE) of the randomized phase 2 LILAC trial who received ...
Richard Furie   +8 more
wiley   +1 more source

Placebo-Induced Changes in fMRI in the Anticipation and Experience of Pain

open access: yesScience, 2004
T. Wager   +8 more
semanticscholar   +1 more source

A Randomized, Double‐Blind, Placebo‐Controlled Trial of Abatacept for the Treatment of Relapsing, Nonsevere Granulomatosis With Polyangiitis

open access: yesArthritis &Rheumatology, EarlyView.
Objective To compare the efficacy of abatacept to placebo for the treatment of relapsing, nonsevere granulomatosis with polyangiitis (GPA). Methods In this multicenter trial, eligible patients with relapsing, nonsevere GPA were randomized to receive abatacept 125 mg subcutaneously once a week or placebo, both together with prednisone 30 mg/day (or ...
Carol A. Langford   +155 more
wiley   +1 more source

PACIFIC-5: a phase III clinical trial of consolidation durvalumab in patients with unresectable stage III NSCLC and no progression after concurrent or sequential chemoradiotherapy. [PDF]

open access: yesJ Hematol Oncol
Wu YL   +19 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy